Company Description
Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease.
It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | May 1, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 59 |
| CEO | Benny Sorensen |
Contact Details
Address: 101 Main Street, Suite 1220 Cambridge, Massachusetts 02142 United States | |
| Phone | (617) 553-3952 |
| Website | hemab.com |
Stock Details
| Ticker Symbol | COAG |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 2114044 |
| CUSIP Number | 423494103 |
| ISIN Number | US4234941031 |
| Employer ID | 41-4241952 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Benny Sorensen M.D., Ph.D. | President, Chief Executive Officer and Director |
| Mads Nikolaj Behrndt-Eriksen M.Sc. | Chief Financial Officer and GM |
| Dr. Catherine Eilleen Madigan M.D. | Chief Medical Officer |
| Dr. Ananthram Sreenivasa Murthy M.Sc., Ph.D. | Chief Operating Officer |
| Karen Weisbach | Chief People and Culture Officer |
| Cecile Bonvoisin M.Sc. | Senior Vice President of CMC and Manufacturing |
| Tara O'Meara | Senior Vice President of Development Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 12, 2026 | SCHEDULE 13G | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 7, 2026 | SCHEDULE 13G | Filing |
| Aug 6, 2026 | SCHEDULE 13G | Filing |
| Aug 5, 2026 | SCHEDULE 13G | Filing |
| May 21, 2026 | 10-Q | Quarterly Report |
| May 21, 2026 | 8-K | Current Report |
| May 11, 2026 | SCHEDULE 13G | Filing |
| May 11, 2026 | SCHEDULE 13D | Filing |